Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ4MCG)

Drug Name

KB-6806 Drug Info

Synonyms

Prucalopride succinate; 179474-85-2; Prucalopride Succinat; Prucalopride (succinate); UNII-4V2G75E1CK; R-108512; BUTANEDIOIC ACID 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-[1-(3-METHOXYPROPYL)-4-PIPERIDINYL]-7-BENZOFURANCARBOXAMIDE; Prucalopride succinate [USAN]; 4V2G75E1CK; R 108512; AK175654; Prucalopride succinate (USAN); resotran; Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1); Butanedioic acid, compd. with 4-amino-5-chloro-2,3-dihydro-N-[1-

Indication

Disease Entry	ICD 11	Status	REF
Chemotherapy-induced nausea	MD90	Phase 2	[1]

Cross-matching ID

PubChem CID: 3073291
CAS Number: CAS 148014-93-1
TTD Drug ID: DMZ4MCG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 3 receptor (5HT3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ondansetron	DMOTQ1I	Chemotherapy-induced nausea	MD90	Approved	[2]
Granisetron	DMIUW25	Malignant glioma	2A00.0	Approved	[3]
Ramosetron	DMH7GN8	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[4]
Y-25130	DMDPM7R	Nausea and vomiting	MD90	Approved	[5]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[6]
LITOXETINE	DMKZRBP	Mood disorder	6A60-6E23	Phase 3	[7]
Zatosetron maleate	DMWDEFC	Anxiety disorder	6B00-6B0Z	Phase 3	[8]
Pancopride	DMIRYU9	Nausea	MD90	Phase 3	[9]
Lerisetron	DMOTCIU	Nausea	MD90	Phase 3	[1]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3 receptor (5HT3R)	TTNXLKE	NOUNIPROTAC	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
2	Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
3	New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
4	Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
5	The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
6	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
7	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
8	Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
9	Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
10	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.